While Sanofi's antacid medicine Zantac (ranitidine) and its generic versions face immediate withdrawal in the US due to nitrosamine impurities, the European Medicines Agency is continuing to conduct its own review of ranitidine-containing medicines and “will formulate an opinion in due course.”
The next discussion on the safety of ranitidine medicines is foreseen later this month when the EMA’s human medicines evaluation...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?